Schaunaman, Niccolette
Cervantes, Diana
Nichols, Taylor
Numata, Mari
Ledford, Julie G.
Kraft, Monica
Chu, Hong Wei
Funding for this research was provided by:
National Institutes of Health (U19AI125357, U19AI125357, U19AI125357, U19AI125357, U19AI125357, U19AI125357, U19AI125357)
Article History
Received: 26 March 2024
Accepted: 23 April 2024
First Online: 3 May 2024
Declarations
:
: The animal study protocol was approved by the Institutional animal care and use committee (IACUC) of National Jewish Health (AS2792-03-26).
: Not applicable.
: Drs. Ledford and Kraft are co-founders of RaeSedo, LLC, a company to develop novel peptidomimetic based therapeutics derived from an active area of SP-A. No peptidomimetic studies are reported in this manuscript. All other authors declare no conflict of interest.